Advertisement

Topics

Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress

06:30 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the Europe...

Other Sources for this Article

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com

NEXT ARTICLE

More From BioPortfolio on "Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...